ImCare Biotech has been awarded Phase II grant by NCI (NIH) for its project on development of a diagnostic kit for early detection of liver cancer.
Tag: imcare biotech
-
Imcare Biotech has entered into a development partnership with Harvard Medical School.
-
Imcare Biotech has entered into a development partnership with Ohio State University.
-
Imcare Biotech has entered into a development partnership with Thomas Jefferson University.
-
ImCare has developed a new Anti-SPINK1 antibody (BA1), which recognizes native human pancreatic secreted SPINK1/TATI/PSTI in WB and ELISA. More information about this monoclonal antibody and the ELISA kit based on this monoclonal antibody, please contact info@imcarebiotech.com
-
USA patent application 13/991943 Serine Protease Inhibitor Kazal antibodies (Inventor: X. Lu and T. Block) has been filed.
-
A novel technology named Immune-absorbance real time PCR (IA-PCR) with extremely high sensitivity as PCR and great specificity as ELISA has been developed by ImCare Biotech. This technology can be used to quantify any enveloped viruses. Based on this technology, a high-throughput screening system has been established by ImCare Biotech and is successfully used to identify anti-viral drugs.
-
USA patent Number US8193328B2: Identification of modulators of serine protease inhibitor Kazal (SPIK) and their use as anti-cancer and anti-viral agent (Inventor Xuanyong Lu and T. Block) has been published on 6/5/2012. This patent protects ImCare Biotech to study and develop their products.
-
ImCare Biotech signed strategic co-operation with South-Central University for Nationalities (China) and Hubei Cancer Hospital